Skip to main content

Vedolizumab (Entyvio)

Vedolizumab is a monoclonal antibody for the treatment of ulcerative colitis and Crohn's disease.

It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1), blocking it, and resulting in gut-selective anti-inflammatory activity.

It is administered through intravenous infusion every 8 weeks.

It has an immunogenicity rate of 4-10%.

Labs that test for drug level:

KU Leuven
Sheba Medical Centre
United Medix Labs

Labs that test for ADA titre:

KU Leuven
United Medix Labs